ClinicalTrials.gg
CompletedNCT05905367SIFIUpdated Mar 16, 2026

Symptom-inhibited Fentanyl Induction

A Phase 4 interventional study of Fentanyl and Methadone in Opioid Use Disorder, sponsored by Pouya Azar. Completed at 1 site in Canada. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Pouya Azar · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 36 studies in Opioid-Related Disorders with a site in Canada — 11 open to participants now, 12 under way, 1 of them phase 3. Opioid-Related Disorders · Canada.

Enrollment
18th of 32
48 · median 51
Started
2024
with 3 others
Phase 4
9 of 36
3 open now
Registered
27th of 36
by date
Lead sponsor
3 of 36
Pouya Azar

Among the 36 studies in Opioid-Related Disorders with a site in Canada, this one is the 18th largest by enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2024, is one of 9 in phase 4, and was the 27th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

11 of the 36 studies in Opioid-Related Disorders with a site in Canada are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Opioid-Related Disorders with a site in Canada, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test a treatment strategy for individuals with opioid use disorder (OUD) who use fentanyl. Participants will receive medically-administered doses of intravenous (IV) fentanyl at intervals until they are comfortable and do not have withdrawal symptoms. They then will be given opioid agonist therapy (OAT) once daily by mouth, which is the current standard treatment for OUD. In this trial, each participant's starting dose of OAT will be tailored to meet their opioid needs, based on the amount of IV fentanyl they received.

The main questions this trial aims to answer are:

  • Is the IV fentanyl protocol feasible and safe for use in a community clinic setting?
  • Will the protocol result in higher-than-standard starting doses of OAT? Are these doses safe, and will they enable participants to stay on OAT for a longer time?
Read the detailed description

This is an open-label, single arm, prospective clinical trial involving 50 individuals with opioid use disorder (OUD) who use illicit fentanyl and for whom opioid agonist therapy (OAT) with either methadone or slow-release oral morphine (SROM) is clinically indicated. Participants who provide informed consent and are found to be eligible will undergo a "symptom-inhibited" fentanyl induction procedure under close medical supervision in a community clinic. A study doctor or nurse will administer intravenous (IV) fentanyl at 5-minute intervals until the participant indicates comfort and their opioid withdrawal symptoms are minimized, or until their sedation level is 2 on the Pasero Opioid-induced Sedation Scale (POSS). Immediately before the first dose of fentanyl, after each dose during the induction procedure, and every 5 minutes for 15 minutes (or until stable) after the final fentanyl dose, study staff will monitor the participants' level of sedation (POSS), withdrawal symptoms (Clinical Opiate Withdrawal Scale, COWS), and vital signs (heart rate, respiratory rate, blood pressure, oxygen saturation).

Selection of the appropriate OAT agent for each participant will be done in advance by the clinical addictions management team. Participants with a QTc interval >500 msec on screening ECG will not be eligible to receive methadone, and will be offered SROM if clinically appropriate. Participants with known chronic kidney disease will have serum creatinine tested for calculation of estimated glomerular filtration rate (eGFR) if they are to receive SROM; if eGFR is between 15 and 60 mL/min, SROM doses will be adjusted according to current recommendations [Lexicomp 2021]; if eGFR\<15 mL/min, the participant will not be eligible to receive SROM.

The total cumulative dose of IV fentanyl administered during the induction phase (the loading dose) x 8 will be used as a proxy for the individual's 24-hour opioid tolerance, which in turn will be converted to oral morphine equivalents and used to calculate the appropriate starting dose of methadone or SROM, up to a maximum daily dose of 200 mg for methadone or 2000 mg for SROM. The first OAT dose will be administered under observation in the clinic, preferably on the same day and 15-30 minutes after the completion of the induction procedure. Participants will remain in the clinic under observation for 3 hours after the first dose of methadone or SROM. Vital signs, POSS, and COWS will be monitored before the first OAT dose, then hourly and prior to discharge. Study staff will assess the participants' satisfaction with the symptom-inhibited fentanyl induction process, using the single item Medication Satisfaction Questionnaire (MSQ) and 3-open ended questions. Participants will be discharged from the clinic when medically stable.

Participants will return to the study clinic once daily for 7 days for OAT dispensing and assessment of activity level in the previous 24 hours, vital signs, POSS, and COWS. An ECG will be performed on OAT Days 3 (+/- 2 days) and 7 (+/- 2 days) for participants receiving methadone. Methadone will be preferentially be maintained at the same dose for the first 7 days; however, methadone dose may be adjusted (up to a maximum daily dose of 200 mg) if felt to be safe and clinically indicated. SROM doses may be increased by 100 mg every 24-48 hours (consistent with current clinical guidelines from the British Columbia Centre on Substance Use) up to a maximum daily dose of 2000 mg if clinically indicated (presence of cravings or withdrawal symptoms, and absence of SROM-related adverse events and opioid toxicity).

After Day 7, OAT will be dispensed through a community pharmacy according to standard procedure. Participants will return to the study clinic for the following assessments at 7 days (up to +2 days) , 1 month (+/- 2 weeks), 3 months (+/- 1 month), 6 months (+/- 2 months), and 12 months (+/- 3 months) post-induction:

  • Participant satisfaction with their current OUD treatment (single-item MSQ)
  • Whether maintained on oral OAT and, if so, current dose
  • Whether on prescribed opioids for risk mitigation, and if so, type and dose
  • Self-reported illicit opioid use - type, route, amount, frequency
  • Self-reported use of other substances - type, route, amount, frequency
  • Withdrawal symptoms (COWS score)
  • Urine drug test

At the same time points, additional information will be obtained from the clinic's electronic medical record (EMR) database:

  • Overdose events requiring intervention (acute care or hospitalization)
  • Hospitalizations, including diagnosis, route of admission, dates, duration
  • Survival; if deceased, cause of death
03

Conditions studied

  • Opioid Use Disorder

Keywords

  • Fentanyl
  • Methadone
  • Morphine
  • Opioid agonist therapy
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Opioid use disorder (OUD) of any severity by Clinical Diagnostic criteria
  2. Intentional use of unregulated fentanyl by any route (injection and/or inhalation) by participant self-report
  3. Urine drug test (UDT) positive for fentanyl at screening or within 7 days prior to date of screening visit
  4. Clinical indication to start OAT with methadone or SROM
  5. Willing and able to provide written for study participation
  6. If taking prescribed opioids for safer supply/risk mitigation, willing to discontinue them starting on study Day 1 and for the first 7 days of the study

Exclusion criteria

Exclusion Criteria:

  1. Individuals who are pregnant or breast-feeding
  2. Currently receiving prescribed fentanyl in any form, e.g. fentanyl patch
  3. Previous participation in this study
  4. Current use of methadone >150mg/day or SROM >1300mg/day or buprenorphine extended-release in any dose
  5. Use of buprenorphine-naloxone within the previous 3 days
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Symptom-inhibited IV fentanyl induction

    Symptom-inhibited IV fentanyl induction followed by opioid agonist therapy (OAT) with either oral methadone or slow-release oral morphine (SROM)

    Drug: Fentanyl · Drug: Methadone · Drug: Slow-release oral morphine

Interventions

  • Symptom-inhibited IV fentanyl induction

    Also known as: Fentanyl citrate, Fentanyl injection

  • Opioid agonist therapy (OAT) with methadone at starting doses established by symptom-inhibited IV fentanyl induction

    Also known as: Methadone hydrochloride, Methadone oral product

  • DrugMorphineStudies of MorphineMorphine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Opioid agonist therapy (OAT) with SROM at starting doses established by symptom-inhibited IV fentanyl induction

    Also known as: SROM, Kadian

06

What researchers measure

Primary outcomes

  1. Number of clinically significant study drug-related adverse events requiring intervention

    Total number of clinically significant study drug-related adverse events (e.g. sedation, respiratory depression, hypoxia, QT prolongation) requiring intervention, occurring during the first week

    Time frame: Count starting from the beginning of the IV fentanyl induction procedure up to the end of Day 7 on OAT

Secondary outcomes

  1. Starting doses of oral OAT

    Starting doses of methadone or slow-release oral morphine (SROM)

    Time frame: Immediately after IV fentanyl induction

  2. OAT retention

    Proportion of participants who are retained on OAT

    Time frame: Days 1-7 and 1, 3, 6, and 12 months after IV fentanyl induction

  3. Participant satisfaction with fentanyl induction

    Qualitative interview and single-item Medication Satisfaction Questionnaire (MSQ)

    Time frame: First 1 to 3 hours after IV fentanyl induction

  4. Participant satisfaction with current OAT

    Single-item MSQ

    Time frame: Before IV fentanyl induction, and at Day 7 and 1, 3, 6, and 12 months after IV fentanyl induction

  5. Withdrawal symptoms

    Clinical Opiate Withdrawal Scale (COWS) score

    Time frame: Before, during, and during 1-3 hours after IV fentanyl induction; daily during first week on OAT; and at 1, 3, 6, and 12 months

  6. Overdose events

    Opioid overdose events requiring Intervention (acute care or hospitalization)

    Time frame: Day 7 and 1, 3, 6, and 12 months

  7. Hospitalizations

    Inpatient hospital admissions for any cause

    Time frame: Day 7 and 1, 3, 6, and 12 months

  8. Death

    Death

    Time frame: Day 7 and 1, 3, 6, and 12 months

07

Study locations

1 site
  • Hope to Health Research & Innovation Centre
    Vancouver, British Columbia V6A 1H2, Canada
08

References and documents

Publications

  • Azar P, Ignaszewski MJ, Harris M, Barazanci Z, Davison R, Wong JSH, Maharaj A, Mathew N, Hall D, Guillemi SA, Foreman J, Barrios R, Montaner JSG. Rapid intravenous symptom-inhibiting fentanyl induction (SIFI) to optimize rotation onto oral opioid agonist therapy among individuals who use unregulated fentanyl: protocol for an open-label, single arm clinical trial. Addict Sci Clin Pract. 2025 Jul 29;20(1):58. doi: 10.1186/s13722-025-00586-7. PubMed 40731024 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Dec 2025, 23 months.

Of 48 non-industry phase 4 interventional studies under Opioid-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 55. This study's 23 months is below that.

Counting every sponsor, half of 52 studies reached it within 32 months; a quarter within 20 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2023
First posted
Jun 15, 2023
StartActual
Jan 29, 2024
Primary completionActual
Dec 31, 2025
CompletionActual
Dec 31, 2025
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05905367
Lead sponsor
Pouya Azar
Responsible party
Pouya Azar (Principal Investigator, University of British Columbia) — Sponsor-investigator
First posted
Jun 15, 2023
Start date
Jan 29, 2024
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025
Last update
Mar 16, 2026

Study contacts

Pouya Azar, MD
principal investigator · University of British Columbia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fentanyl

Start the discussion